Vistagen Therapeutics 관리

관리 기준 확인 1/4

Vistagen Therapeutics CEO는 Shawn Singh, Aug2009 에 임명되었습니다 의 임기는 15.25 년입니다. 총 연간 보상은 $ 947.92K, 65.7% 로 구성됩니다. 65.7% 급여 및 34.3% 보너스(회사 주식 및 옵션 포함). 는 $ 81.86K 가치에 해당하는 회사 주식의 0.12% 직접 소유합니다. 81.86K. 경영진과 이사회의 평균 재임 기간은 각각 1.7 년과 8.7 년입니다.

주요 정보

Shawn Singh

최고 경영자

US$947.9k

총 보상

CEO 급여 비율	65.7%
CEO 임기	15.3yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	1.7yrs
이사회 평균 재임 기간	8.7yrs

최근 관리 업데이트

Recent updates

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

Nov 15

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Sep 08

VistaGen drops 80% as late-stage study for anxiety therapy fails

Jul 22

Here's Why We're Not Too Worried About VistaGen Therapeutics' (NASDAQ:VTGN) Cash Burn Situation

Apr 10

VistaGen Therapeutics added to Russell 2000 Index

Jun 16

VistaGen Therapeutics (NASDAQ:VTGN) Is In A Strong Position To Grow Its Business

Jun 07

VistaGen Therapeutics slumps in after hours trade on underwritten public offering

Dec 17

CEO 보상 분석

Shawn Singh 의 보수는 Vistagen Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$40m
Jun 30 2024	n/a	n/a	-US$33m
Mar 31 2024	US$948k	US$623k	-US$29m
Dec 31 2023	n/a	n/a	-US$32m
Sep 30 2023	n/a	n/a	-US$35m
Jun 30 2023	n/a	n/a	-US$46m
Mar 31 2023	US$600k	US$600k	-US$59m
Dec 31 2022	n/a	n/a	-US$64m
Sep 30 2022	n/a	n/a	-US$65m
Jun 30 2022	n/a	n/a	-US$60m
Mar 31 2022	US$1m	US$563k	-US$49m
Dec 31 2021	n/a	n/a	-US$62m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	US$1m	US$511k	-US$42m
Dec 31 2020	n/a	n/a	-US$16m
Sep 30 2020	n/a	n/a	-US$17m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	US$934k	US$498k	-US$22m
Dec 31 2019	n/a	n/a	-US$24m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$28m
Mar 31 2019	US$951k	US$466k	-US$26m
Dec 31 2018	n/a	n/a	-US$24m
Sep 30 2018	n/a	n/a	-US$20m
Jun 30 2018	n/a	n/a	-US$18m
Mar 31 2018	US$1m	US$425k	-US$16m

보상 대 시장: Shawn 의 총 보상 ($USD 947.92K )은 US 시장( $USD 652.28K ).

보상과 수익: 회사가 수익성이 없는 동안 Shawn 의 보상이 증가했습니다.

CEO

Shawn Singh (61 yo)

15.3yrs

테뉴어

US$947,917

보상

Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....

리더십 팀

이름	위치	테뉴어	보상	소유권
Shawn Singh	CEO & Director	15.3yrs	US$947.92k	0.12% $ 81.9k
Cynthia Anderson	VP & Chief Financial Officer	1.3yrs	US$434.19k	0.013% $ 9.4k
Joshua Prince	Chief Operating Officer	2yrs	US$568.44k	0.0099% $ 7.0k
Reid Adler	Chief Corporate Development Officer & General Counsel	2.5yrs	US$675.00k	0.061% $ 43.1k
Mark McPartland	Senior Vice President of Investor Relations	1.6yrs	US$479.99k	데이터 없음
Trisha Fitzmaurice	Senior Vice President of Human Resources	no data	데이터 없음	데이터 없음
Allen Cato	Senior Vice President of Development Operations	no data	데이터 없음	데이터 없음
Mark Ginski	Senior VP and Head of Chemistry	3.8yrs	데이터 없음	데이터 없음
Mark Flather	Senior Vice President of Corporate Strategy & Capital Markets	1.6yrs	데이터 없음	데이터 없음
Erik Berglund	Senior Vice President of Global Regulatory Affairs & Pharmacovigilance	1.3yrs	데이터 없음	데이터 없음
Louis Monti	Senior Vice President of Translational Neuroscience	less than a year	데이터 없음	데이터 없음
Jessica Haskell	VP, Associate General Counsel & Secretary	1.8yrs	데이터 없음	데이터 없음

1.7yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: VTGN 의 관리팀은 경험 (평균 재직 기간 1.7 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Shawn Singh	CEO & Director	13.8yrs	US$947.92k	0.12% $ 81.9k
Jon Saxe	Independent Director	24.8yrs	US$129.37k	0.0069% $ 4.9k
Jerry Gin	Independent Director	8.7yrs	US$128.12k	0.049% $ 34.8k
Gordon Keller	Chairman of Scientific Advisory Board	1.9yrs	데이터 없음	데이터 없음
Thomas Laughren	Member of Clinical & Regulatory Advisory Board	8.7yrs	데이터 없음	데이터 없음
Maurizio Fava	Member of Clinical & Regulatory Advisory Board	9.1yrs	데이터 없음	데이터 없음
Michael Liebowitz	Member of CNS Clinical and Regulatory Advisory Board	6.1yrs	데이터 없음	데이터 없음
Margaret FitzPatrick	Independent Chair of the Board	3.3yrs	US$185.62k	0% $ 0
Mark Steven Wallace	Member of Clinical & Regulatory Advisory Board	7.3yrs	데이터 없음	데이터 없음
Gerard Sanacora	Member of Clinical & Regulatory Advisory Board	9.8yrs	데이터 없음	데이터 없음
Mary Rotunno	Independent Director	3.3yrs	US$128.12k	0% $ 0
Sanjay Mathew	Member of Clinical & Regulatory Advisory Board	8.7yrs	데이터 없음	데이터 없음

8.7yrs

평균 재임 기간

64yo

평균 연령

경험이 풍부한 이사회: VTGN 의 이사회는 경험(평균 재직 기간 8.7 년)으로 간주됩니다.

Vistagen Therapeutics 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer

Vistagen Appoints Cindy Anderson as Chief Financial Officer

Vistagen Therapeutics, Inc., Annual General Meeting, Sep 25, 2023

Vistagen Therapeutics, Inc. Announces Retirement of Jerrold D. Dotson, Chief Financial Officer, Effective on or About August 31, 2023

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 14, 2022

Recent updates

We're Hopeful That Vistagen Therapeutics (NASDAQ:VTGN) Will Use Its Cash Wisely

Second quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Vistagen to Present At the 2024 Neuroscience Education Institute Congress

Vistagen Therapeutics, Inc. to Report Q2, 2025 Results on Nov 07, 2024

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Consensus revenue estimates increase by 161%

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: EPS exceeds analyst expectations

New minor risk - Market cap size

Vistagen Therapeutics, Inc. to Present At the 2024 American Society of Clinical Psychopharmacology Conference

Vistagen Announces Positive Results from Phase 2A Pilot Study of Ph15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Consensus EPS estimates upgraded to US$1.60 loss, revenue downgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Vistagen Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Vistagen Therapeutics, Inc. to Report Q3, 2024 Results on Feb 13, 2024

Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain

Vistagen Therapeutics, Inc. to Report Q2, 2024 Results on Nov 09, 2023

Vistagen Therapeutics, Inc. Appoints Joshua Prince as the Chief Operating Officer

New major risk - Shareholder dilution

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder

Vistagen Appoints Cindy Anderson as Chief Financial Officer

Vistagen Therapeutics, Inc. Announces Positive Phase 3 Trial Results from Phase 3 Palisade-2 Trial of Rapid-onset Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder (SAD)

Vistagen Therapeutics, Inc. to Report Q1, 2024 Results on Aug 10, 2023

New major risk - Share price stability

Vistagen Announces Positive Top-Line Results from Phase 3 PALISADE-2 Trial of Fasedienol (PH94B) Nasal Spray in Social Anxiety Disorder

Vistagen Therapeutics, Inc., Annual General Meeting, Sep 25, 2023

Vistagen Therapeutics, Inc. Announces New Mechanism of Action Data from Preclinical Tissue Distribution Study in Laboratory Rats

Vistagen Therapeutics, Inc. Reports New Preclinical Data Supporting Itruvone (PH10) Nasal Spray's Potential Antidepressant Activity Via Peripheral Nasal Neurons Without Entry into the Brain

Vistagen Therapeutics, Inc. Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease

Vistagen Therapeutics, Inc. Announces Retirement of Jerrold D. Dotson, Chief Financial Officer, Effective on or About August 31, 2023

Vistagen Regains Full Compliance with Nasdaq Listing Requirements

Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Vistagen Announces European Patent Office Intention to Grant New PH80 Nasal Spray Patent for the Treatment of Migraine

VistaGen Therapeutics, Inc. Announces Positive Results from Exploratory Phase 2A Study of PH80 in Women Diagnosed with Menopausal Hot Flashes

Vistagen Provides Nasdaq Compliance Update

Forecast to breakeven in 2026

VistaGen Therapeutics, Inc. to Report Q3, 2023 Results on Feb 07, 2023

VistaGen Therapeutics, Inc. (NasdaqCM:VTGN) completed the acquisition of Pherin Pharmaceuticals, Inc.

Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder

Vistagen Announces Completion of Last Patient, Last Visit in Phase 2 Clinical Trial of PH94B for the Treatment of Adjustment Disorder with Anxiety

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder

Vistagen Receives FDA "Study May Proceed" Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder

VistaGen Therapeutics, Inc. Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

Price target decreased to US$2.82

VistaGen Therapeutics, Inc. to Report Q2, 2023 Results on Nov 10, 2022

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 28, 2022

Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects

Vistagen Therapeutics, Inc. Announces Completion of an Interim Analysis of PALISADE-2

VistaGen to proceed with phase 3 anxiety nasal spray trial following interim analysis

Vistagen Therapeutics Receives Letter from Nasdaq Regarding Non-Compliance of Minimum Bid Price

VistaGen Therapeutics, Inc., Annual General Meeting, Oct 14, 2022

CEO & Director recently bought US$103k worth of stock

Consensus forecasts updated

Forecast to breakeven in 2025

Consensus forecasts updated

Price target decreased to US$3.36

Vistagen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug Ph94b

VistaGen drops 80% as late-stage study for anxiety therapy fails

Consensus revenue estimates fall by 32%

No longer forecast to breakeven

VistaGen Therapeutics, Inc. Terminates Employment of H. Ralph Snodgrass as President and Chief Scientific Officer

VistaGen Therapeutics, Inc. to Report Fiscal Year 2022 Results on Jun 23, 2022

CEO & Director exercised options to buy US$120k worth of stock.

VistaGen Announces Key Regulatory Update on Ph94b for the Acute Treatment of Social Anxiety Disorder

VistaGen Therapeutics, Inc. Appoints Reid Adler as Chief Legal Officer

Forecast to breakeven in 2025

VistaGen Therapeutics, Inc. to Present Preclinical Data on Lead Candidate PH94B At Upcoming Scientific Congresses